| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Unité de Sommeil, Service de Pneumologie, CHU d'Angers, Angers, and 2 Unité de Sommeil, Service de Pneumologie, CHU Saint Antoine, Paris, France
CORRESPONDENCE: N. Pelletier-Fleury, Institut National de la Santé et de la Recherche Médicale U537 (Centre de Recherches en Economie et Gestion Appliquées à la Santé), 80 rue du Général Leclerc, 94276, Le Kremlin-Bicêtre Cedex, France. Fax: 33 146713270. E-mail: fleury@kb.inserm.fr
Keywords: apnoea, continuous positive airway pressure, costs, economic evaluation
Received: June 13, 2003
Accepted September 4, 2003
This study was supported by the Programme Hospitalier de Recherche Clinique n°9706
The objective of this study was to measure the impact of a 6-month delay in the diagnosis and treatment of patients with moderate obstructive sleep apnoea syndrome (OSAS) (apnoea/hypopnoea index (AHI) <30) or severe OSAS (AHI
This study was conducted as a multicentre randomised controlled trial and carried out at two teaching hospitals in France. A total of 171 patients were followed for 6 months, with 82 patients randomised to group 1 "immediate polysomnography" and 89 in group 2 "polysomnography within 6 months".
Patients with severe OSAS were deprived of a significant improvement of their daytime sleepiness (5.1±5.0 at the Epworth Sleepiness Scale score in group 1 versus 0.2±3.4 in group 2) and quality of life (12.4±13.3 at the Nottingham Health Profile score in group 1 versus 0.7±10.1 in group 2) during the waiting time. The impact of delayed management in subjects with less severe OSAS only concerned daytime sleepiness (1.9±3.3 in group 1 versus 0.3±4.3 in group 2). Delayed treatment did not affect cognitive functions or healthcare expenditure regardless of the severity of the disease. Incremental cost effectiveness ratios related to rapid introduction of treatment were significantly lower in the patients with more severe OSAS.
These results provide fairly clear medical and economic arguments in favour of early management of patients with more severe forms of obstructive sleep apnoea syndrome.
30) on daytime sleepiness, cognitive functions, quality of life and healthcare expenditure (hospitalisations, medical visits, complementary tests, biological tests and drug prescriptions). In addition, this study aimed to analyse the incremental cost effectiveness ratios related to daytime sleepiness or quality of life following immediate introduction of treatment in these two populations.
This article has been cited by other articles:
|
|
 |
|
  J Amit Benjamin and K E Lewis Sleep-disordered breathing and cardiovascular disease Postgrad. Med. J., January 1, 2008; 84(987): 15 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. P. Patel, M. Ahmed, and I. Rosen Split-Night Polysomnography Chest, November 1, 2007; 132(5): 1664 - 1671. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. T. McNicholas, M. R. Bonsignore, and the Management Committee of EU COST ACTION B26 Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities Eur. Respir. J., January 1, 2007; 29(1): 156 - 178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Ghiassi, K Murphy, and M R Partridge Delays in diagnosis of OSAHS Thorax, June 1, 2004; 59(6): 540 - 540. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
